Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

December 27, 2019 00:23:35
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?
Critical Care Perspectives in Emergency Medicine
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

Dec 27 2019 | 00:23:35

/

Show Notes

Up to one-third of patients with status epilepticus will not respond to benzodiazepines.  Unfortunately, treatment of benzodiazepine-refractory status epilepticus is not well studied.  The longer seizures persist, the worse patients do.  In this podcast, we discuss the results of the recently completed ESETT trial that evaluated three anticonvulsant medications for status epilepticus.

You can get CME credit for this episode here!Click here for CME Account Creation Instructions

Other Episodes

Episode 0

June 24, 2019 00:26:09
Episode Cover

Anticoagulation Reversal for ICH

ICH accounts for approximately 15 percent of all strokes.  Despite improvements in neurocritical care, the mortality for patients with ICH can still reach 50...

Listen

Episode 0

August 29, 2021 00:22:03
Episode Cover

The BaSICS Trial - Implications for Fluid Resuscitation

The administration of IVFs is nearly universal in critically ill patients.  In recent years, several studies have suggested improved outcomes with the use of...

Listen

Episode 0

March 05, 2020 00:26:10
Episode Cover

COVID-19 Update - March 2020

In December 2019 a novel coronavirus (now named COVID-19) was identified as responsible for a cluster of pneumonia cases in Wuhan, China. As of...

Listen